Scalper1 News
Danish pharmaceutical giant Novo Nordisk (NVO) missed Q1 sales estimates and lowered its full-year revenue forecast Thursday, though profit was in line. Novo stock was down more than 2% in early trading on the stock market today. Novo made 45 cents a share in the quarter, up about 10% over the year-earlier quarter in Danish kroner, and a penny above analysts’ consensus. Sales increased 2% in kroner to the equivalent of $3.73 billion, missing Scalper1 News
Scalper1 News